Hepatitis C Relapse Leads to Gilead Woes
Share
Follow Us
The Editors at Hepatitis Central
February 20, 2012
Because three quarters of Hepatitis C patients relapsed after stopping Gilead’s GS-7977, the company’s financial profile suffered.
Gilead Drops After Patients Relapse on Hepatitis C Drug
By Meg Tirrell
Feb. 17 (Bloomberg) — Gilead Sciences Inc., which fueled a land grab for hepatitis C therapies with its $10.8 billion purchase last year of Pharmasset Inc., dropped the most in 11 years after some patients on the acquired experimental medicine relapsed after stopping therapy.
Among eight patients with hepatitis C genotype 1, the most common form of the disease in the U.S., six had a viral relapse within four weeks after stopping a 12-week regimen with the medicine, GS-7977, plus ribavirin, Gilead said today in a statement. The other patients in the trial are two weeks out from stopping treatment, and haven’t relapsed, the company said.
Continue reading this entire article:
